1 of 1
Story summary
- Novartis halted development of its experimental ALS drug VHB937 after the Phase 2 ASTRALS trial missed primary and secondary endpoints.
- The ASTRALS study enrolled 251 early-stage ALS patients and tested VHB937’s TREM2-stabilizing mechanism.
- Novartis agreed to pay $125 million for Sironax’s platform that transports large-molecule therapies across the blood-brain barrier.
- The failure follows recent Phase 3 setbacks for pelacarsen in cardiovascular disease and delpacibart etedesiran in myotonic dystrophy.